PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
68.80
-1.30 (-1.85%)
At close: 5:24PM IST
Stock chart is not supported by your current browser
Previous Close70.10
Open70.10
Bid72.40 x 128000
Ask1.00 x 209400
Day's Range68.40 - 70.10
52 Week Range63.00 - 198.00
Volume163,943
Avg. Volume227,440
Market Cap97.9M
Beta (3Y Monthly)2.74
PE Ratio (TTM)N/A
EPS (TTM)-0.16
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update

    CARMIEL, Israel, Nov. 7, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of ...

  • PR Newswire

    Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019

    Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel, Oct. 29, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company ...

  • PR Newswire

    Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease

    CARMIEL, Israel, Oct. 17, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (PLX.TA), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced positive 12-month on-treatment data from the first 16 out of the 22 adult patients enrolled in its BRIDGE Phase III study. "We previously announced positive preliminary results from 16 patients after six months in the BRIDGE study in September 2018, and these new results, after 12 months of treatment, further suggest the strong potential benefit of pegunigalsidase alfa on renal function for Fabry patients," said Raul Chertkoff, M.D., Protalix's Vice President, Medical Affairs.

  • PR Newswire

    Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease

    CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (PLX.TA), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and its development and commercialization partner, Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced the completion of enrollment in their Phase III BALANCE clinical study of pegunigalsidase alfa, or PRX‑102, for the treatment of Fabry disease. The head-to-head Phase III BALANCE clinical study is designed to evaluate the safety and efficacy of PRX‑102 compared to agalsidase beta (Fabrazyme®) on renal function in Fabry patients with progressing kidney disease previously treated with agalsidase beta.

  • GlobeNewswire

    Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

    CARMIEL, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins including a late-stage clinical product expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it received a deficiency letter from NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(a)(i) – (iii) of the NYSE American Company Guide (the “Company Guide”) as it has reported a stockholders’ equity deficiency as of June 30, 2019 and net losses in its five most recent fiscal years ended December 31, 2018.

  • GlobeNewswire

    Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships

    CARMIEL, Israel, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it has engaged a first-tier financial advisory firm to assist the Company in evaluating and pursuing strategic alternatives to maximize stakeholder value. Dror Bashan, Protalix’s President and Chief Executive Officer commented, “We have three key initiatives as a management team which include improving our capital structure, pursuing strategic partnerships and alliances and actively moving our pipeline toward commercialization.”  The Company also reported that it is actively pursuing potential partnering discussions for its other pipeline candidates, OPRX-106, an orally-delivered anti-inflammatory treatment, and alidornase alfa, a modified form of recombinant DNase (rhDNASE), as well as partnerships with other company’s compounds combined with Protalix’s ProCellEx® platform.

  • GlobeNewswire

    Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics

    Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA) today announced that Shlomo Yanai has resigned from the Company’s Board of Directors for personal reasons, effective today. Mr. Yanai has served on the Board of Directors and as the Company’s Chairman of the Board since July 2014. With the announcement of Mr. Yanai’s resignation, the Board of Directors unanimously elected Zeev Bronfeld, a current independent director, as Chairman of the Board.

  • GlobeNewswire

    Protalix BioTherapeutics Reports Second Quarter 2019 Results and Provides Corporate Update

    CARMIEL, Israel, Aug. 08, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019

    CARMIEL, Israel, July 29, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire

    Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer

    CARMIEL, Israel, July 29, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA) today announced that Eyal Rubin has been appointed to serve as the Company’s new Senior Vice President and Chief Financial Officer, effective September 22, 2019.  Yossi Maimon will continue to work with the Company’s finance and accounting teams to ensure a smooth transition of the Company’s financial and accounting functions until Mr. Rubin begins. “I am very happy to introduce Eyal to the Protalix team where he will bring valuable financial and accounting experience and knowledge,” said Dror Bashan, Protalix’s President and Chief Executive Officer.  “We wish Yossi success in his future endeavors.  Yossi has played a critical role in Protalix’s leadership enabling Protalix to advance our pipeline development during his tenure.

  • GlobeNewswire

    Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease

    CARMIEL, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the completion of enrollment in the phase III BRIGHT clinical trial of pegunigalsidase alfa, or PRX‑102, for the treatment of Fabry disease, via intravenous (IV) infusions of 2 mg/kg administered every 4 weeks.  PRX‑102 is the Company’s plant cell-expressed recombinant, PEGylated, cross-linked α‑galactosidase‑A drug candidate. The BRIGHT study is a 12 month, open-label switchover study to assess the safety, efficacy and pharmacokinetics (PK) of pegunigalsidase alfa 2 mg/kg administered every 4 weeks in up to 30 Fabry patients previously treated with an enzyme replacement therapy (ERT): Fabrazyme® or Replagal®.  To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with stable kidney disease.  Patients that matched the criteria were enrolled in the study and switched from their current treatment of intravenous (IV) infusions every 2 weeks to 2 mg/kg of PRX‑102 every 4 weeks for 12 months.

  • GlobeNewswire

    Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States

    Protalix BioTherapeutics, Inc. (NYSE American: PLX) (PLX.TA), or Protalix, and Chiesi Farmaceutici S.p.A, an international research-focused healthcare Group, or Chiesi, today announced that, following a series of meetings and correspondence with the U.S. Food and Drug Administration (FDA), they plan to file a biologics license application, or a BLA, for pegunigalsidase alfa for the treatment of Fabry disease in the first quarter of 2020 via the FDA’s Accelerated Approval pathway.

  • GlobeNewswire

    Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director

    CARMIEL, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA) today announced that Dror Bashan has been appointed to serve as the Company’s new President and Chief Executive Officer, and a director, effective June 30, 2019, replacing Moshe Manor, who is stepping down from those roles for personal reasons.  Mr. Manor will assist with the transition and continue to work with the Company on a consultant basis.

  • Associated Press

    Protalix: 1Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 5 cents. The drug developer posted revenue of $10.4 million in the period. The company's shares closed at 44 cents. A year ...

  • GlobeNewswire

    Protalix BioTherapeutics Reports 2019 First Quarter Results and Provides Corporate Update

    CARMIEL, Israel, May 06, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Protalix BioTherapeutics to Hold First Quarter 2019 Financial Results and Corporate Update Conference Call on May 6, 2019

    CARMIEL, Israel, April 29, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire

    Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update

    CARMIEL, Israel, March 18, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization.

  • GlobeNewswire

    Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call

    CARMIEL, Israel, March 13, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire

    Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019

    CARMIEL, Israel, March 06, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire

    Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019

    CARMIEL, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) --  Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that preliminary pharmacokinetic (PK) data from its phase III BRIGHT study of pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease is the subject of an oral presentation at the 15th Annual WORLDSymposiumTM 2019.  The conference is taking place February 4-8, 2019 at the Hyatt Regency Orlando, Orlando, Florida, and the oral presentation is scheduled for Thursday, February 7, 2019 at 8:30 AM ET. PRX-102 is the Company’s plant cell-expressed recombinant, PEGylated, cross-linked α-galactosidase-A drug candidate for the treatment of Fabry disease.  The BRIGHT study is a 12-month, open-label switchover study to assess the safety, efficacy and pharmacokinetics of pegunigalsidase alfa 2 mg/kg administered every 4 weeks in up to 30 Fabry patients previously treated with an enzyme replacement therapy (ERT): Fabrazyme® or Replagal®.  As of December 23, 2018, 28 patients had been enrolled in the BRIGHT study, and 15 of those patients had completed 9 months of treatment.  Samples from these 15 patients underwent pharmacokinetic (PK) evaluation and were tested for the presence of anti-drug antibodies (ADA).

  • GlobeNewswire

    Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019

    CARMIEL, Israel, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that the Company will present preliminary pharmacokinetic (PK) data from its phase III BRIGHT study of pegunigalsidase alfa for the treatment of Fabry disease at the 15th Annual WORLDSymposium™ 2019.  The conference will take place February 4-8, 2019 at the Hyatt Regency Orlando, Orlando, Florida. Preliminary results of a Phase 3 study,” highlighting PK and safety data will be presented by Mr. Myrl D. Holida, PA, of the University of Iowa Health Care in Iowa City, Iowa, a principal investigator in the Company’s clinical trial of PRX-102 for the treatment of Fabry disease, on Thursday, February 7, 2019 at 8:30 AM ET.

  • GlobeNewswire

    Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease

    CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the completion of enrollment for the BRIDGE phase III clinical trial of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Additionally, the Company provided an update on the enrollment for the BALANCE and BRIGHT phase III clinical trials which, collectively with the BRIDGE study, comprise the phase III clinical development program for PRX-102 for the treatment of Fabry disease.  The BRIGHT study is approximately 90% enrolled and the BALANCE study is approximately 70% enrolled.